ChemDiv, a California-based global provider of integrated drug discovery solutions, announced on Friday that it is continuing to provide chemistry, computational and clinical pharmacology support to Clywedog Therapeutics.

The company is taking this step as it enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ: BRNS). The merged company will operate under the name Clywedog Therapeutics Inc and is expected to be listed on Nasdaq under the ticker CLYD upon closing.

The merged portfolio will concentrate on advancing clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D), and celiac disease.

ChemDiv's ongoing partnerships includes accelerated CMC research, AI-enabled pharmacology, computational modelling and translational biology, extending the successful transition of Clywedog's programs to the clinic in 2023-2024.